Dignify Therapeutics


Edward Burgard, Ph.D.

Ed Burgard, PhD was Co-founder and Director of Cellular Pharmacology at Urogenix Inc.  Prior to that he held positions of Director of In vitro Pharmacology at Dynogen Pharmaceuticals, and Research Investigator at Abbott Laboratories.  Dr. Burgard received his PhD in Pharmacology from the Uniformed Services University School of Medicine and completed postdoctoral training at the University of Alabama, Birmingham and the University of Michigan.

Karl B. Thor, Ph.D.

Karl Thor, PhD was most recently Co-founder and VP of Research of Urogenix Inc., a subsidiary of Astellas Pharma.  Prior to that, he was Founder and CSO of Dynogen Pharmaceuticals, Founder and CSO of PPD GenuPro, Co-Director of the Laboratory of NeuroUrology at Duke University Medical Center, and Research Scientist at Eli Lilly. Dr. Thor has served as a member of the FDA-PhRMA Industry Guidelines for Urinary Incontinence Trials, the NIH Urology Special Emphasis Study Section, and serves on the WHO’s International Consultation on Incontinence.

Lesley Marson, Ph.D.

Lesley Marson, PhD  was most recently Director of Sexual Health Research at Urogenix Inc.  Prior to that she held the position of Professor in the Urology Division of the Department of Surgery, University of North Carolina, Chapel Hill.  Here she directed a successful NIH-funded a preclinical research program and served as Study Coordinator for several clinical trials. Prior to that Dr Marson was Assistant Professor at Northwestern University, Chicago and completed postdoctoral training at Washington University St Louis and University of Kentucky, Lexington. She is an internationally-recognized expert in pelvic and sexual function.

Velu Karicheti, Ph.D.

Velu Karicheti, PhD was most recently Co-founder and Sr. Director of Research Operations at Urogenix Inc.  Prior to that he held positions of Director of Model Development at Urogenix Inc, Senior Scientist at Dynogen Pharmaceuticals, and Scientist II at Millenium Pharmaceuticals.  Dr. Karicheti received his PhD in Biomedical Engineering from the Indian Institute of Technology, and completed postdoctoral training in urology at the Albert Einstein College of Medicine.

Dan Ricca, Ph.D.

Dan Ricca, PhD began his professional career in medicinal chemistry at Glaxo.  He subsequently co-founded SARCO, a combinatorial chemistry company, where he served as VP of Chemistry.  Following a successful acquisition and exit, Dan assumed the role of VP of Chemistry for two small venture-backed drug discovery companies, Cogent Neuroscience and Dynogen Pharmaceuticals.  Dan holds a PhD in Medicinal Chemistry from the University of Michigan and completed a post-doctoral fellowship at the University of California, Irvine.

Aura Kullmann, Ph.D.

Aura Kullmann, PhD was most recently Principal Scientist at Urogenix Inc.  Dr. Kullmann received her PhD in Neurobiology from the University of Pittsburgh School of Medicine and completed postdoctoral training in urology in the Pharmacology Department of the University of Pittsburgh.

Eboo Versi, MD, Ph.D.

Eboo Versi, MD, PhD  is Chief Medical Officer (CMO) of Eboo Pharmaceuticals.   He is also President of Versi Consulting LLC and previously served as Head of Development and CMO at Mt Cook Pharma Inc, Senior Vice President of Development at Plethora Solutions, Vice President of Medical Affairs at Astellas (Yamanouchi) and Director of Urology and Women’s Health at Pfizer (Pharmacia). He is a member of the Royal College of Obstetricians and Gynecologists and received his bachelor’s and doctorate degrees from Oxford University and his medical degree from Cambridge University.

Benny Ward

Benny Ward has almost 15 years of financial, operations and management experience working with life science companies. He most recently served as Executive Vice President, Business Development and Strategy, of a specialty pharma company, and was VP of Finance and Chief Financial Officer of InnerPulse, a development stage cardiac rhythm management device company. Prior to joining InnerPulse, Mr. Ward was Vice President of Finance and Chief Financial Officer of Closure Medical Corporation, a world-leading, publicly traded developer and manufacturer of biomaterial-based medical adhesives that was acquired by Johnson & Johnson.

Tatyana Touzova

Tatyana Touzova, MS was most recently Senior Director of Quality and CMC of USA operations at Synthon Pharmaceuticals, Inc., and is the founder of NanoClimate consulting firm. She is a professional with over 25 years of experience in drug development, and commercial manufacturing of pharmaceuticals, combination products and medical devices. Through her professional career Mrs. Touzova contributed to the advancement of numerous drug leads and marketed pharmaceuticals at Biogen (currently BiogenIdec), Diosynth (Fujifilm), Biolex Therapeutics, and Synthon Pharmaceuticals. She also provides consulting regulatory and CMC support to Bio/Pharmaceutical and medical device companies from discovery to clinical and commercial manufacturing. Mrs. Touzova received her M.S. in Bioengineering from Moscow Mendeleyev Institute of Chemical Technology, Department Microbiology and Biotechnology. Mrs. Touzova hosted PDA conference in US, presented at the regulatory conferences in US and Europe, and author of several scientific papers.

Mary Katofiasc

Mary Katofiasc was most recently Regulatory Affairs and Quality Assurance Manager at Hemo bioscience. Prior to that she held positions of Manager of Research Operations at Urogenix Inc., Senior Research Associate at Dynogen Pharmaceuticals and Biologist in the Neuroscience Research Division at Eli Lilly. Ms. Katofiasc has over 20 years of experience in Urology and Neuroscience in vivo research. She completed her biology degree at Purdue University.